Synthesis and κ-opioid receptor activity of furan-substituted salvinorin A analogues.
Andrew P Riley, Chad E Groer, David Young, Amy W Ewald, Bronwyn M Kivell, Thomas E Prisinzano
Journal of medicinal chemistry December 26, 2014 DOI: 10.1021/jm501521d via PubMed
Summary
AI-generated from the abstractSalvinorin A, a compound from the leaves of Salvia divinorum, activates κ-opioid receptors and could be a basis for treating substance abuse. Researchers synthesized several derivatives with modified furan rings to better understand how this part of the molecule binds to the receptor. Functional assays showed that smaller substitutions are preferred, indicating the furan ring fits into a tight part of the binding pocket. The most potent analogue reduced drug-seeking behavior in an animal model of relapse without causing sedation, a common side effect of other κ-opioid agonists.
Study at a glance
| Characteristics | Experimental study Peer reviewed |
|---|---|
| Population | Animal model |
| Intervention | salvinorin A derivatives with modified furan rings |
| Citations | 115 |
| Key finding | The most potent salvinorin A analogue reduced drug-seeking behavior in an animal model of relapse without causing sedation. |
Abstract
The neoclerodane diterpene salvinorin A, found in the leaves of Salvia divinorum, is a potent κ-opioid receptor agonist, making it an attractive scaffold for development into a treatment for substance abuse. Although several successful semisynthetic studies have been performed to elucidate structure-activity relationships, the lack of analogues with substitutions to the furan ring of salvinorin A has prevented a thorough understanding of its role in binding to the κ-opioid receptor. Herein we report the synthesis of several salvinorin A derivatives with modified furan rings. Evaluation of these compounds in a functional assay indicated that sterically less demanding substitutions are preferred, suggesting the furan ring is bound in a congested portion of the binding pocket. The most potent of the analogues successfully reduced drug-seeking behavior in an animal model of drug-relapse without producing the sedation observed with other κ-opioid agonists.